January 14th, 2015
Innovation in the interest of public health happens faster when researchers in both the public and private sectors share information and work together. We’ve seen this happening to the greatest extent during the current Ebola epidemic. Imagine if this were the new culture and the new standard in science. If done responsibly so that we could also maintain a healthy R&D ecosystem, sharing data from clinical studies can help advance the science that is the foundation of all medical care.
Our primary responsibility, as one of the most broadly based healthcare companies in the world, is to the doctors and nurses, patients and consumers, mothers, fathers and children who use our products. That means taking a patient and consumer-centered approach to advancing medical science through all of our products that touch people in different ways. It also means we have the opportunity to set the standard and be leaders and role models in advancing best practices that will ultimately advance science and medicine.
When we announced early last year that we would partner with the Yale School of Medicine Open Data Access Project (YODA) to serve as an independent reviewer for every request for clinical data from our pharmaceutical studies, we broke new ground in data transparency.